Filed on 4 March 2022 in the U.S. District Court for the District of Delaware before Judge Colm F. Connolly, this case saw Novo Nordisk A/S assert ten U.S. patents against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. The asserted patents span semaglutide injection formulations, delivery devices, and related pharmaceutical compositions — the same active ingredient at the core of Ozempic, one of the world’s best-selling GLP-1 receptor agonist therapies. Dr. Reddy’s had sought to market generic versions of semaglutide injection at 2 mg/1.5 ml and 4 mg/3 ml concentrations.

The action was resolved on 16 October 2024 through a Stipulation and Order of Dismissal signed by Judge Connolly, reflecting a privately negotiated settlement agreement between the parties. All claims, counterclaims, affirmative defenses, and demands were dismissed without prejudice, and both parties expressly waived any right to appeal or seek further relief from the stipulation. Critically, no costs, disbursements, or attorneys’ fees were awarded to either side — a symmetrical outcome that reveals little about which party held the stronger negotiating position.

The 957-day duration suggests meaningful pre-trial engagement before settlement was reached. The dismissal without prejudice — rather than with prejudice — leaves open theoretical avenues for future filings, though the express appeal waiver and settlement agreement suggest the parties regard this as a final commercial resolution. The confidential terms of the settlement are not disclosed in the public record, meaning any licensing arrangements, market entry timelines, or royalty structures agreed between Novo Nordisk and Dr. Reddy’s remain unknown. Given the commercial scale of the Ozempic franchise, the settlement terms are likely to be commercially significant.